论文部分内容阅读
Many small-molecule compounds have been evaluated with potential antiproliferative activities. Ethyl 1-(phenylcarbamoyl)-2-(3,4,5-trimethoxyphenyl)cyclopropanecarboxylate, one novel cyclopropylamide analogue of combretastatin-A4(CA-4), has been synthesized and its crystal structure was characterized by X-ray single-crystal diffraction. The crystal belongs to monoclinic, space group P21/n, with a = 15.0263(3), b = 7.6574(2), c = 19.4117(4), β = 111.9010(10)o, V = 2072.36(8)3, Z = 4, C22H24NO6, Mr = 398.42, Dc = 1.277 Mg/cm3, F(000) = 844, λ(MoKα) = 1.54178 , μ = 0.770 mm–1, R = 0.0546 and wR = 0.1889 for 3319 observed reflections(I > 2σ(I)). Meanwhile, the compound revealed potential antiproliferative activities in several cancer cells in vitro.
Many small-molecule compounds have been evaluated with potential antiproliferative activities. Ethyl 1- (phenylcarbamoyl) -2- (3,4,5-trimethoxyphenyl) cyclopropanecarboxylate, one novel cyclopropylamide analogue of combretastatin-A4 and its crystal structure was characterized by X-ray single-crystal diffraction. The crystal belongs to monoclinic space group P21 / n with a = 15.0263 (3), b = 7.6574 (2), c = 19.4117 β = 111.9010 (10) o, V = 2072.36 (8) 3, Z = 4, C22H24NO6, Mr = 398.42, Dc = 1.277 Mg / cm3, F (000) = 844, λ (MoKα) = 1.54178 , μ = 0.770 mm-1, R = 0.0546 and wR = 0.1889 for 3319 observed reflections (I> 2σ (I)). Meanwhile, the compound revealed potential antiproliferative activities in several cancer cells in vitro.